DETAILED ACTION
This action is in response to Applicant’s submission dated August 5, 2026, in which Applicant elected the species of Compound 3. Once this species was not found in the art outside of the instant application and its patent family, the full scope of the claimed invention was searched in the art.
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Information Disclosure Statement
The references contained in the IDS dated February 23, 2024 are made of record.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention.
Claims 1-19 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Jefferson, et al, New Inhibitors of Bacterial Protein Synthesis from a Combinatorial Library of Macrocycles, J. of Med. Chem., Vol. 45, No. 16, pp. 3430-3439 (2002). Jefferson et al. teaches compound 16, which is disclosed in connection with a pharmaceutical use as an antibacterial and specifically teaches a test against Staphylococcus aureus is mentioned among the strains used for the biological tests (see p. 3434, right column).
Claims 1-18 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Argawal, et al, US 2021/0177827. Argawal, et al. teaches PAPD5 inhibitors and methods of use thereof for disease treatment, which include instant compounds. Specifically, the compounds with the structures:
PNG
media_image1.png
1522
540
media_image1.png
Greyscale
of the reference anticipates the aforementioned claims where R1 is H, R2 is methyl, R4 is substituted phenyl, R4a is H.
Conclusion
Any inquiry concerning this communication or earlier communications from the Examiner should be directed to ERICH A LEESER whose telephone number is (571) 272-9932. The Examiner can normally be reached Monday through Friday from 10-6 PST, M-F. PST.
If attempts to reach the Examiner by telephone are unsuccessful, the Examiner’s supervisor, Mr. James Alstrum-Acevedo can be reached at (571) 272-5548. The fax number for the organization where this application is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) toll-free at 866-217-9197. If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/ERICH A LEESER/Primary Examiner, Art Unit 1622
United States Patent and Trademark Office
Tel. No.: (571) 272-9932
